Valuation: Cogent Biosciences, Inc.

Market Cap 7.24B 6.27B 5.85B 5.37B 10.1B 690B 10.26B 68.66B 26.95B 346B 27.21B 26.61B 1,143B P/E 2026 *
-18.6x
P/E 2027 * -51.9x
Enterprise Value 7.19B 6.22B 5.81B 5.33B 10.02B 684B 10.18B 68.14B 26.74B 343B 27B 26.41B 1,134B EV / Sales 2026 *
726x
EV / Sales 2027 * 20.6x
Free-Float
98.82%
Yield 2026 *
-
Yield 2027 * -
1 day+1.41%
1 week+8.89%
Current month+8.89%
1 month+5.95%
3 months+21.85%
6 months+14.32%
Current year+19.34%
1 week 37.4
Extreme 37.4
43.39
1 month 37.04
Extreme 37.04
43.39
Current year 30.87
Extreme 30.87
43.39
1 year 10.72
Extreme 10.72
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Free

Director

627 0.0004%
09/06/26 Free

Director

17,901 0.0105%
09/06/26 Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+1.41%+8.89%+290.33%+284.32% 7.24B
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.60%+11.40%+76.65%+214.72% 27.08B
Weighted average by Cap. +4.28%+12.98%+55.92%+171.59%

Financials

2026 *2027 *
Net sales 9.9M 8.57M 8M 7.34M 13.8M 942M 14.02M 93.85M 36.84M 472M 37.19M 36.37M 1.56B 349M 302M 282M 259M 486M 33.2B 494M 3.31B 1.3B 16.64B 1.31B 1.28B 55.02B
Net income -392M -339M -316M -290M -546M -37.27B -554M -3.71B -1.46B -18.68B -1.47B -1.44B -61.75B -132M -114M -106M -97.58M -184M -12.53B -186M -1.25B -490M -6.28B -495M -484M -20.77B
Net Debt -55.22M -47.76M -44.6M -40.92M -76.96M -5.26B -78.18M -523M -205M -2.63B -207M -203M -8.71B -63.88M -55.25M -51.6M -47.33M -89.03M -6.08B -90.44M -605M -238M -3.05B -240M -235M -10.07B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
07/08/26 $42.39 +1.41% 1,855,791
06/08/26 $41.80 -1.11% 1,043,363
05/08/26 $42.27 -1.33% 1,881,062
04/08/26 $42.84 +10.24% 4,748,703
03/08/26 $38.86 -0.18% 1,406,506
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
42.39USD
Average target price
54.25USD
Spread / Average Target
+27.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock